Keyphrases
Advanced Squamous Cell Carcinoma
100%
Central Review
28%
Cetuximab
14%
Chemoradiotherapy
14%
Cisplatin
100%
Complete Response Rate
57%
Epidermal Growth Factor Receptor
42%
Epidermal Growth Factor Receptor Inhibitors
14%
Erlotinib
100%
Fluorescence in Situ Hybridization
14%
Follow-up Time
14%
Hazard Ratio
14%
Head-and-neck
100%
Locally Advanced
100%
Locally Advanced SCCHN
14%
Patient Characteristics
14%
Phase II Trial
100%
Progression-free Survival
42%
Radiotherapy
100%
Radiotherapy Alone
14%
Rash
14%
Small Molecule Inhibitors
14%
Squamous Cell Carcinoma of Head
100%
Tumor
14%
Well-balancing
14%
Pharmacology, Toxicology and Pharmaceutical Science
Cetuximab
20%
Chemoradiation Therapy
20%
Cisplatin
100%
Epidermal Growth Factor Receptor
80%
Erlotinib
100%
Progression Free Survival
60%
Rash
20%
Squamous Cell Carcinoma
100%
Immunology and Microbiology
Arm
100%
Cetuximab
12%
Epidermal Growth Factor
50%
Fluorescence in Situ Hybridization
12%
Neck
100%
Progression Free Survival
37%
Squamous Cell
100%